Advancing Clinical Evaluation and Treatment of Arthrogenic Muscle Inhibition: A Need for Validation and Innovation-Letter to the Editor.

Autor: Norte GE, Sherman DA, Rush JL, Ingersoll CD, Bodkin SG, Snyder-Mackler L, Grindstaff TL, Burland JP, Hopkins JT, Blackburn T, Chaput M, Konishi Y, Rice DA, Hart JM, Harkey MS, Zarzycki R, Palmieri-Smith RM, Lepley LK, Lepley AS, Pamukoff DN, Park J, Lisee C, Pietrosimone B, Thomas AC, Goetschius J, Tourville TW, Kidgell DJ, Kuenze CM
Jazyk: angličtina
Zdroj: The American journal of sports medicine [Am J Sports Med] 2024 Oct; Vol. 52 (12), pp. NP34-NP36.
DOI: 10.1177/03635465241272410
Abstrakt: Competing Interests: One or more of the authors has declared the following potential conflict of interest or source of funding: T.B. is a co-inventor for a patent-pending rehabilitation device demonstrated to acutely reduce AMI (US patent application No. 17/914,305). AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.
Databáze: MEDLINE